NAD+ therapy: separating the signal from the noise

If you've spent any time researching longevity, anti-aging, or biohacking, you've almost certainly run into NAD+ therapy. Nicotinamide adenine dinucleotide -- NAD+ -- is a coenzyme found in every living cell, and it's essential for hundreds of metabolic processes, from energy production to DNA repair. Levels decline naturally with age, and that simple biological fact has launched an entire industry of IV drips, injections, and supplements promising to turn back the clock.

Here's the thing: the biology behind NAD+ is genuinely fascinating and well-established. But the leap from "this molecule matters" to "this therapy will reverse your aging" is much bigger than most clinic marketing materials would have you believe. Let's walk through what the science actually shows, where the real promise lies, and how to track your protocol if you decide NAD+ therapy is worth exploring.

What NAD+ Does and Why It Declines

The basics of cellular energy

NAD+ is a workhorse molecule. It shuttles electrons between reactions in your mitochondria, making it essential for converting food into cellular energy (ATP). It's also a required substrate for sirtuins -- a family of proteins involved in DNA repair, inflammation regulation, and cellular stress response. Without adequate NAD+, these processes slow down.

By your 40s and 50s, tissue NAD+ levels may have dropped by 50% or more compared to your 20s. That decline correlates with many hallmarks of aging: reduced mitochondrial function, increased inflammation, impaired DNA repair, and metabolic dysfunction.

The decline in NAD+ with age isn't controversial. The question is whether raising it back up through external supplementation produces the outcomes people are hoping for.

Why the science got exciting

Animal studies painted a compelling picture. Mice given NAD+ precursors showed improved mitochondrial function, better insulin sensitivity, enhanced physical endurance, and even extended lifespan in some models. These weren't fringe studies -- they came from labs at Harvard, the NIH, and other top institutions.

That preclinical excitement is what fueled the current NAD+ therapy industry. But as we'll see, the translation from mice to humans has been humbling.

The Three Delivery Methods: IV, Injection, and Oral

Not all NAD+ therapy is the same. The delivery method changes the cost, the experience, the evidence base, and potentially the results. Here's an honest comparison.

IV NAD+ infusions

IV infusions are the most dramatic (and expensive) option. Clinics often market them as transformative experiences, and some people do report immediate clarity, energy, or mood improvements during or after a drip. But there's an important caveat that often gets buried.

Dr. Eric Verdin, President of the Buck Institute for Research on Aging, has been direct about this: NAD+ is too large a molecule to easily enter cells when injected intravenously. Much of it gets broken down into nicotinamide before it can be used. A pilot study comparing IV NAD+ to IV nicotinamide riboside (NR) found that NR IV actually produced more robust increases in NAD+ concentration, and the infusion time was 75% shorter. The NAD+ IV group also showed increases in white blood cells and neutrophils, suggesting a possible inflammatory response that wasn't seen with NR.

IV NAD+ therapy has the weakest clinical evidence of the three delivery methods, despite being the most expensive. That doesn't mean it can't help -- it means we don't have strong data proving it does.

Subcutaneous injections

SubQ NAD+ injections offer a middle ground. They bypass digestion, they're self-administered at home after proper training, and they're significantly cheaper per dose than IV infusions. However, the human clinical data for this delivery method is the most sparse. Most of the supporting evidence comes from case reports and clinic-level observations rather than controlled trials.

Oral supplementation: NMN and NR

Oral precursors -- nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) -- have the most human trial data of any NAD+ intervention. Rather than delivering NAD+ directly, these molecules are one or two enzymatic steps away from NAD+ in the biosynthesis pathway, and your body converts them after absorption.

A head-to-head human trial comparing NMN, NR, and nicotinamide (Nam) found that both NMN and NR approximately doubled circulating NAD+ levels after 14 days of supplementation, while Nam only produced a brief acute spike. A 2026 study published in Nature Metabolism added an intriguing finding: gut bacteria appear to play a role in converting NMN and NR to nicotinic acid, and both precursors modulated gut microbiota to increase short-chain fatty acids -- molecules believed to strengthen the gut barrier and reduce systemic inflammation.

What the Human Evidence Actually Shows

This is where we need to be really honest, because there's a significant gap between what the marketing says and what the clinical data supports.

What's well-established

• NAD+ levels increase reliably. Both NMN and NR consistently elevate circulating NAD+ levels by roughly 100-150% in human trials. This is reproducible and not in dispute.
• Safety profile is favorable. Across multiple trials, oral NMN and NR at typical doses (250-2,000 mg/day for NR; 250-1,200 mg/day for NMN) have been well-tolerated with no serious adverse events.
• Biological plausibility is strong. The mechanism connecting NAD+ to cellular repair, energy metabolism, and sirtuin activity is backed by decades of solid biochemistry.

What's promising but unproven

• Cognitive benefits. Some NMN trials have reported improved cognitive scores relative to placebo, and the NADPARK study in Parkinson's disease found that NR preserved mitochondrial NAD+ in dopaminergic neurons. But a study giving NMN to healthy older men raised NAD+ levels sixfold with no measurable change in cognitive function. Results are inconsistent.
• Physical performance. A systematic review and meta-analysis of NMN and NR's effects on skeletal muscle mass and function found the evidence "inconclusive." Some trials show modest improvements; others show nothing.
• Long-COVID recovery. A randomized controlled trial of high-dose NR (2,000 mg/day) in long-COVID patients showed increased NAD+ levels and some symptom improvement, but the results require replication.

What's not proven in humans

• Lifespan extension. No human trial has demonstrated that NAD+ supplementation extends lifespan. The mouse data is interesting, but mice are not humans.
• Visible anti-aging. Claims about reversing wrinkles, restoring youthful skin, or dramatically turning back the biological clock have no supporting human clinical data.
• Disease reversal. While NAD+ therapy is being studied for Alzheimer's, Parkinson's, and metabolic diseases, no trial has yet shown convincing disease-modifying effects in humans.

Raising NAD+ levels is the easy part. The hard question -- and the one still being answered -- is whether those higher levels translate into outcomes you can actually feel and measure.

Making Sense of the Hype Cycle

Why people feel like it's working

It's worth acknowledging that many people who try NAD+ therapy -- especially IV infusions -- report feeling genuinely better. More energy, clearer thinking, improved mood. These experiences are real, and dismissing them entirely would be unfair.

But several factors complicate the picture. The placebo effect is powerful, especially for expensive interventions administered in clinical settings. Hydration from the IV itself can produce noticeable effects. And people who invest $1,000 in a therapy are often simultaneously improving their sleep, nutrition, and exercise habits -- creating confounders that are nearly impossible to untangle without controlled trials.

The preclinical translation problem

The gap between animal and human results for NAD+ therapies is one of the most discussed issues in aging research. Mice given NMN or NR show dramatic improvements in nearly every aging marker. Humans given the same precursors show... higher NAD+ levels. The functional downstream benefits have been modest or absent in most trials to date.

This doesn't mean NAD+ therapy is useless. It may mean we need longer trials, different dosing strategies, better outcome measures, or that the benefits accumulate slowly over years in ways that short trials can't capture. But we should be honest about where the evidence stands right now.

What to watch for in the next few years

The research pipeline is active. Ongoing trials are investigating NAD+ precursors for Alzheimer's disease, Parkinson's, type 2 diabetes, multiple sclerosis, and breast cancer. Longer-duration studies with more rigorous endpoints are underway. If NAD+ therapy is going to prove its clinical worth beyond raising a biomarker, these studies will be the ones to watch.

How to Track Your NAD+ Protocol

If you've weighed the evidence and decided to explore NAD+ therapy with your clinician's guidance, tracking your protocol properly is one of the most valuable things you can do. NAD+ protocols vary widely -- different delivery methods, doses, frequencies, and combinations -- and your individual response is the data that matters most.

What to log every session

Whether you're doing IV infusions, SubQ injections, or taking daily oral supplements, consistency in tracking creates a personal dataset you can actually learn from.

For every dose, record:

• Delivery method and specific product
• Exact dose (mg for oral; dose and volume for injections)
• Time of administration
• Whether taken with food (for oral) or fasting
• Any immediate side effects (nausea, flushing, injection site reactions)

Daily subjective markers worth tracking:

• Energy level (1-10 scale, same time each day)
• Sleep quality and duration
• Cognitive clarity or brain fog
• Exercise performance or recovery feel
• Overall mood

If you're combining NAD+ precursors with other supplements or medications -- which many people in longevity-focused protocols do -- tracking everything in one place prevents the "I changed three things and don't know which one helped" problem.

Why a dedicated tracker matters

Spreadsheets work until they don't. The real challenge isn't recording a single dose; it's maintaining the habit over weeks and months so you can spot patterns. Did your energy improve in week three, or was that the week you also started sleeping better? Did the SubQ injections feel different from the oral protocol, or did you change doses at the same time?

A medication tracking app with reminders and dose history solves this. It turns an inconsistent habit into a reliable system, and gives you something concrete to bring to your next clinician visit.

The best NAD+ protocol is one you can track, adjust, and discuss with your provider using real data -- not memory and guesswork.

Building your protocol into a routine

NAD+ therapy doesn't exist in isolation. Most people taking NMN or NR are also managing other supplements, medications, or health protocols. The key to medication adherence is building your protocol into an existing routine rather than treating it as a separate task. Pair your morning NMN dose with something you already do every day. Set your tracking app to prompt you at that same time. Let the system carry the cognitive load so you can focus on how you're actually feeling.

If you're working from a medication schedule template, add your NAD+ protocol as a line item alongside everything else. One system, one view, one habit.

The Bottom Line on NAD+ Therapy

NAD+ is genuinely important biology. The decline in NAD+ levels with age is real, the metabolic pathways are well-characterized, and the preclinical data is compelling. Oral NMN and NR reliably raise NAD+ levels in humans, they appear safe at commonly used doses, and the research pipeline is active and growing.

But we're still in the early chapters of the human evidence story. The leap from "this raises a biomarker" to "this reverses aging" hasn't been made yet in rigorous human trials. IV infusions are the least evidence-supported and most expensive option. Oral precursors have the strongest data, but even there, the functional benefits remain modest and inconsistent across studies.

If you decide NAD+ therapy is worth exploring -- and reasonable people can land on either side of that decision -- approach it with clear eyes. Work with a clinician who understands the evidence landscape. Choose your delivery method based on data, not marketing. And track your protocol carefully, because your own response over time is the most relevant dataset you'll have.

Done Dose helps you track oral supplements, injectable protocols, and complex medication routines in one place -- with reminders, dose history, and the kind of consistency that turns a protocol into actual data. Whether you're exploring NAD+ precursors or managing a full longevity stack, Done Dose keeps everything organized so you can focus on how you feel, not whether you remembered your dose.

Start tracking your protocol today at Done Dose